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Abstract
Objective: To determine the inﬂ  uence of various patient-speciﬁ  c factors, use of concomi-
tant medications, and weekly vitamin K intake on total weekly warfarin maintenance dose 
(TWD). 
Methods: Information collected, via retrospective chart review, included TWD, general demo-
graphics, vitamin K consumption, target INR range, use of alcohol, tobacco, and cytochrome 
P450 (CYP)-inducing medications, and concomitant medications and diseases.
Results: The majority of patients (n = 131) were Caucasian (71%), with more females 
(55%) than males. Use of CYP-inducing medications resulted in the largest correlation 
coefﬁ  cient (r = 0.30). The sample was divided into high warfarin dose (TWD   50 mg) 
and low warfarin dose (TWD   25 mg) patient populations to discern areas where the 
two populations differed. Age and amiodarone use were the only statistically signiﬁ  cant 
differences between the two groups, with high dose patients tending to be younger and to use 
less amiodarone. Age and CYP-inducing medications were found to be the only statistically 
signiﬁ  cant predictors of TWD in the regression analysis. The TWD was 2.4 mg less for each 
additional decade of patient age. The coefﬁ  cient on CYP-inducing medications indicates 
that the concomitant use of a CYP inducer is associated with an increase in TWD of 17.2 
additional milligrams, adjusting for all other variables in the model.
Conclusion: We found concomitant use of CYP inducer, age, height, and ethnicity to have the greatest 
inﬂ  uence on TWD. Positive relationships were found between TWD and the use of CYP450 inducer, 
height, and African American ethnicity. Although it did appear that women required a lower TWD 
than men, this factor contributed mildly. Further studies with a greater sample size may more precisely 
predict the effect of patient-speciﬁ  c factors on TWD, thus uncovering additional relationships. 
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Introduction
Warfarin therapy is widely used for the prevention of thromboembolic events for a variety 
of medical conditions. The dosing of warfarin is patient-speciﬁ  c. Although there are several 
methods to initiate warfarin therapy, most clinicians elect to begin with empiric doses of 
5 mg daily, and titrate as needed to achieve a therapeutic international normalized ratio 
(INR) (Harrison et al 1997; Crowther et al 1999; Ansell et al 2004). Experience shows that 
within a cohort, patients may require as little as 0.5 mg up to as much as 20 mg or greater 
of warfarin daily to maintain a target INR. This large variability in warfarin dose may be 
explained, to some extent, by concomitant medications, gender, nutritional status, liver 
disease, alcohol consumption, diarrhea, hyperthyroidism, fever, chronic heart failure (CHF), 
and more recently, ethnicity. 
For over a decade, evidence has indicated that elderly patients require smaller total 
weekly warfarin maintenance doses (TWD) compared with younger counterparts (Gurwitz 
et al 1992; James et al 1992; Absher et al 2002; Ansell et al 2004; Singla and Morrill 2005). 
Several studies have also suggested that women require lower warfarin doses than do men Therapeutics and Clinical Risk Management 2007:3(3) 500
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(Absher et al 2002). More recently, evidence has shown that 
patients of African American descent require larger doses of 
warfarin to maintain therapeutic INRs (Blann et al 1999; Absher 
et al 2002; Dang et al 2005; Rieder et al 2005). However, little 
evidence is available concerning the impact of other factors, such 
as body mass index (BMI) and vitamin K intake.
Objective
The purpose of this investigation is to determine the inﬂ  uence 
of various patient-specific factors, use of concomitant 
medications, and weekly vitamin K intake on TWD in the 
population of patients at our internal medicine clinic. Clearly 
deﬁ  ned effects of patient factors on warfarin dose may 
better facilitate achievement of therapeutic INRs following 
initiation of warfarin therapy.
Methods
This research was approved by the hospital’s institutional 
review board through the exempt process, thus consent was 
not required for patients.
Study location and population
This study was conducted within a university-based internal 
medicine clinic. All adult patients (18 to 100 years old) who 
were using warfarin therapy and were followed by clinical 
pharmacists for anticoagulation management and education 
were eligible. Additionally, to further reduce confounders, only 
those patients with stable TWD for three consecutive months 
were included. Patients who were deemed as noncompliant 
with warfarin therapy were excluded. Noncompliance was 
deﬁ  ned, per patient report, as missing greater than one dose 
for two consecutive months, as documented in their electronic 
medical record (EMR). Patients with target INR ranges of 2 to 
3 or 2.5 to 3.5 were included, while patients with target INR 
ranges outside of these values were excluded.
Data collection took place via retrospective chart review. 
Information collected included age, gender, ethnicity, weight, 
height, vitamin K consumption, date of warfarin initiation, 
indication, target INR range (either 2.0 to 3.0 or 2.5 to 
3.5) and TWD. Body mass index (BMI) was calculated 
via weight and height. Patients’ weekly dietary vitamin K 
content was quantiﬁ  ed just prior to their anticoagulation 
appointment using a 2-page survey. The presence of various 
health conditions was also collected, such as heart failure 
and thyroid disorders. Use of alcohol, tobacco, amiodarone, 
aspirin, a multivitamin, and cytochrome P450 (CYP) inducers 
were also identiﬁ  ed. Those medications identiﬁ  ed as CYP 
inducers for the purpose of this study included the following: 
carbamazepine, phenobarbital, phenytoin, primidone, 
rifampin, ritonavir, and St. John’s Wort.
Statistical analysis
Descriptive statistics were calculated for the entire sample 
and then separately for high and low warfarin dose 
patients, using a two sample t-test to detect statistically 
significant differences between the two groups. High 
dose was considered to be greater than or equal to 50 mg 
of TWD, while low dose was considered as less than or 
equal to 25 mg. We also examined individual Pearson 
correlation statistics for meaningful associations between 
each of the patient specific variables and TWD. Finally, 
we analyzed an ordinary least squares regression of the 
combined factors in predicting warfarin dose.
Results
A total of 170 patients were provided pharmaceutical care 
for anticoagulation within the internal medicine clinic. Due 
to warfarin noncompliance or unstable weekly warfarin dose, 
36 patients were excluded. An additional three patients were 
excluded for having target INR ranges other than 2.0–3.0 or 
2.5–3.5. A total of 131 patients were analyzed.
Baseline demographics showed those analyzed for the 
study to range in age from 23 to 98 years (mean age 67 years). 
The majority was Caucasian (71%), followed by African 
American (29%), with more females (55%) than males. De-
scriptive statistics for the sample are summarized in Tables 1 
and 2, including indications for warfarin therapy and weekly 
vitamin K intake for 77 patients. 
The mean weight, height, and BMI were 83.9 kg, 
172 cm, and 28.4 kg/m2, respectively. The most common 
indications for warfarin use were atrial ﬁ  brillation (n = 69, 
50%), deep vein thrombosis (DVT) (n = 32, 23%), pul-
monary embolism (PE) (n = 16, 21%), cerebral vascular 
accident (CVA) or transient ischemic attack (TIA) (n = 20, 
15%), and valve replacement (n = 13, 9%). The majority 
of patients had INR target ranges of 2.0 to 3.0 (n = 115 
out of 131, or 87.8%). Concomitant medication use and 
presence of CHF and thyroid disorders are also presented 
in Table 1.
Simple pairwise correlation statistics between each 
of the variables and TWD are presented in Table 3. The 
concomitant use of CYP-inducing medications resulted in 
the largest correlation coefﬁ  cient (r = 0.30). The difference 
in mean TWD between patient groups who did and did not 
use CYP inducers was found to be statistically signiﬁ  cant 
using a paired t-test (p < 0.001).Therapeutics and Clinical Risk Management 2007:3(3) 501
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When the low ( 25 mg TWD, n = 24) versus high 
( 50 mg TWD, n = 105) TWD patient groups were 
analyzed to discern areas where the two populations 
differed, age and CYP were the only statistically 
significant differences. Those patients within the high 
dose group tended to be younger and to use CYP-inducing 
medications (see Table 4).
We compared those patients consuming >3000 mcg of 
vitamin K per week with those consuming < 250 mcg of vitamin 
K per week and found no difference in the TWD. The mean TWD 
for the lower consumption was 35.8 mg (n = 17), the mean for 
the higher consumption was 37.3 mg (n = 14), and a two sample 
t-test with equal variances concluded no difference (p = 0.83).
Finally, we analyzed an ordinary least squares regres-
sion of the combined factors in predicting warfarin dose 
(see Table 5). Because the regression is restricted to patients 
with no missing data, the resulting sample size was 130. 
Variables with many missing observations, such as vitamin K 
consumption, were excluded from this stage of the analysis 
to preserve sample size and increase the chances of obtaining 
statistically signiﬁ  cant results.
Age and CYP-inducing medications were again found to 
be the only statistically signiﬁ  cant predictors (at the 5% and 
1% levels of signiﬁ  cance, respectively) of TWD. The regres-
sion coefﬁ  cient on age quantiﬁ  es the inverse association with 
dose requirements, while controlling for all other variables 
included in the regression. It indicates that the TWD is 2.4 mg 
less for each additional decade of patient age. The coefﬁ  cient 
on CYP inducers indicates that the concomitant use of a CYP 
inducer is associated with an additional 17.2 mg of warfarin 
a week, while controlling for patient demographics (age, 
BMI, race, gender), medications (amiodarone and aspirin), 
comorbidities (CHF, hypothyroidism, and a history of prior 
thromboembolic event), and tobacco or alcohol use.
Discussion
Our analysis included patients with target INRs of 2–3 
and 2.5–3.5. The correlation coefﬁ  cient of 0.07 indicated 
Table 1 Descriptive statistics for the sample of 131 patients
Continuous variables  Mean value  Standard
   deviation
TWD (mg/week)  36.61  16.03
Age (years)  66.91  13.06
Weight (kg)  83.91  20.91
Height (cm)  172  10.3
BMI (kg/m2) 28.39  6.34
Vitamin K consumption
 (mcg/week)***  1764.93  1745.91
Ethnicity Percentage 
Caucasian 71.0% 
African American  29% 
Dichotomous variables  Percentage 
Female 55.0% 
Amiodarone use  12.1% 
Aspirin use  36.6% 
Tobacco use  9.9% 
Alcohol use  22.1% 
CYP inducer  7.7% 
Multivitamin use**  21.5% 
History of CHF  16.8% 
History of Hypothyroidism  14.6% 
LFT 3× ULN*  1.6% 
Target INR 2.5–3.5  12.9% 
Notes: *Data only available for 129 patients; **Data only available for 130 patients; 
*** Data only available for 77 patients.
Table 2 Descriptive statistics – Indications for warfarin therapy 
(n = 131)
Indications Mean  value
History of atrial ﬁ  brillation  49.6%
History of deep vein thrombosis  24.5%
History of pulmonary embolism  12.2%
Prosthetic valve  10.8%
Other indication for warfarin therapy  21.6%
Table 3 Pearson correlation coefﬁ  cients between TWD and 
patient speciﬁ  c variables
Variable Correlation  coefﬁ  cient
Demographics 
Age  −0.241**
BMI 0.076
Caucasian  −0.109
Female  −0.050
Medication use 
Amiodarone   −0.066
Aspirin   −0.019
CYP inducer  0.300**
Multivitamin   −0.084
LFT 3× ULN  0.042
Comorbidities
CHF  −0.095
Hypothyroidism  −0.112
Prior embolism  0.108
Other patient characteristics
Target INR 2.5–3.5  0.068
Vitamin K consumption  0.026
Tobacco use  −0.004
Alcohol use  0.108
Notes: **Statistically signiﬁ  cant at the 1% level.Therapeutics and Clinical Risk Management 2007:3(3) 502
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that target INR had a relatively low inﬂ  uence on TWD in 
our sample. It was therefore decided to include both target 
populations in an effort to increase power. To check for 
potential bias resulting from this decision, we reran each 
of the analyses on the larger subgroup with INR targets of 
2–3 and found that statistical signiﬁ  cance and directions of 
correlations were unchanged.
As expected, this investigation suggests that one of the 
strongest and statistically signiﬁ  cant patient-speciﬁ  c factors 
that affect TWD is the concomitant use of CYP-inducing 
medications. The predominately active warfarin isomer (S) is 
metabolized through CYP450 2C9, while the less active isomer 
(R) is a substrate of the 1A2, 2C19, and 3A4 isoenzymes. 
Addition of medications that induce the metabolism of these 
enzymes would thus increase plasma warfarin concentrations, 
and thus decrease the TWD need. The concomitant use of CYP 
inducers resulted in the largest correlation coefﬁ  cient (r = 0.30). 
The difference in mean TWD between patient groups that did 
and did not use CYP-inducing medications were found to be 
statistically signiﬁ  cant using a t-test (p < 0.001). Because a 
simple correlation is not adjusted for other patient-speciﬁ  c 
characteristics, the relationship may be confounded. To address 
this issue, we conducted a regression analysis which indicates 
that the concomitant use of a CYP inducer is associated with 
17.2 additional milligrams of warfarin per week, adjusting for 
all other variables in the model. In this investigation, the most 
Table 4 Comparison of high and low warfarin dose patient populations
Variable Low  ( 25mg)   High ( 50mg)   P-value from a two
  warfarin dose   warfarin dose  sample t-test or  
  (n = 35)  (n = 26)  chi-squared test
Demographics
Average TWD  19.4 mg  60.7 mg  <0.0001**
Age 72.3  61.6  0.001**
BMI 27.1  29.3  >0.10
Caucasian (%)  0.77  0.62  >0.10
Female (%)  0.63  0.50  >0.10
Medication use
Amiodarone (%)  0.08  0.09  >0.10
Aspirin (%)  0.37  0.35  >0.10
CYP Inducers (%)  0.0  0.15  0.016*
Multivitamin (%)  0.26  0.23  >0.10
LFT 3× ULN (%)  0.03  0.04  >0.10
Comorbidities
CHF (%)  0.20  0.17  >0.10
Hypothyroidism (%)  0.23  0.12  >0.10
Prior Embolism (%)  0.43  0.50  >0.10
Other patient characteristics
Target INR 2.5–3.5 (%)  0.11  0.19  >0.10
Vitamin K consumption  1881.5  2040.4  >0.10
Tobacco use (%)  0.11  0.04  >0.10
Alcohol use (%)  0.17  0.27  >0.10
Notes: *Statistically signiﬁ  cant at the 5% level; **Statistically signiﬁ  cant at the 1% level.
Table 5 Ordinary least squares regression of weekly warfarin 
dose explained by patient speciﬁ  c variables (n = 130)
Variable Coefﬁ  cient  Standard error
Demographics  
Age  −0.24 0.12*
BMI 0.026  0.233
Caucasian  −2.75 3.42
Female  −2.55 3.08
Medication use   
Amiodarone   −3.35 6.60
Aspirin   −1.62 2.86
CYP inducer  17.19  5.41**
Comorbidities  
CHF  −2.66 3.78
Hypothyroidism  −1.99 4.22
Prior embolism  −0.36 3.01
Other patient
characteristics  
Tobacco use  −5.17 4.74
Alcohol use  3.32  3.46
Notes: R-squared = 0.1676; Adjusted R-squared = 0.0822; *Statistically signiﬁ  cant 
at the 5% level; **Statistically signiﬁ  cant at the 1% level.Therapeutics and Clinical Risk Management 2007:3(3) 503
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commonly used CYP-inducing medications were phenytoin, 
phenobarbital, and primidone; therefore, when initiating 
warfarin therapy in a patient who currently uses one of these 
inducers, the clinician should consider empirically initiating 
therapy at a higher dose.
Age was also a statistically signiﬁ  cant predictor of TWD, 
with a regression correlation coefﬁ  cient of −0.24. This inverse 
association indicates that a TWD of 2.4 fewer milligrams are 
prescribed for each additional decade of patient age, adjusting 
for all other variables in the regression analysis. Similar data 
have been published by Garcia and colleagues (2005) who 
found that as patients age the TWD declined by 0.4 mg per 
year of life. Age was also found to be signiﬁ  cantly different 
between the high and low warfarin dose groups, with high dose 
patients tending to be younger (see Table 4). Patients in the 
low and high categories of warfarin use averaged 72 and 62 
years of age, respectively. These ﬁ  ndings conﬁ  rm previously 
published literature; warfarin dose for maintenance therapy is 
inversely proportional to age (Gurwitz et al 1992; James et al 
1992; Absher et al 2002; Singla and Morrill 2005; Garcia et 
al 2005; Merli 2005).
A very weak correlation existed between gender and 
TWD. Although not statistically signiﬁ  cant, the regression 
analysis quantiﬁ  ed this difference with female patients 
requiring a 2.55 mg lower TWD when compared with males. 
This ﬁ  nding is similar compared with previous studies which 
showed that women require an average of 4.5 mg less of 
warfarin per week (Ansell et al 2004; Garcia et al 2005). 
Conversely, several published articles cite gender to be an 
important factor in predicting warfarin dose (Oates et al 1998; 
Absher et al 2002). Regardless of the effect gender plays in 
warfarin dosing, studies are consistent in reporting lower 
doses required for women compared with men.
We found a weak correlation between ethnicity and TWD 
(r = −0.11), with African American patients requiring greater 
TWD than Caucasian patients. Overall African Americans 
required approximately 2.75 mg more per week to maintain 
a therapeutic INR than did Caucasians, controlling for all 
other variables in the regression. Although not statistically 
signiﬁ  cant, this ﬁ  nding agrees with previous study results 
(Blann et al 1999; Absher et al 2002; Dang et al 2005).
Similarly, we found only a weak correlation between BMI 
and TWD (r = 0.08). Adjusting for all other variables in the 
regression, we found that the small positive association remained, 
though it was not statistically signiﬁ  cant. Several other studies 
found no relationship between BMI or body weight and warfarin 
dose (Gurwitz et al 1992; Oates et al 1998; Blann et al 1999). 
Sconce and colleagues, however, found that height has greater 
predictive value of warfarin dose than does body weight or BMI 
(Sconce et al 2005), while Singla and colleagues found that BMI 
inﬂ  uences TWD equally to gender (r2 = 5.3, p = 0.001) (Singla 
and Morrill 2005). It is currently not clear how much of an effect, 
if any, BMI plays upon TWD.
Although there have been various case reports of the affect 
of tobacco (Evans and Lewis 2005), alcohol (Havrda et al 2005), 
and aspirin use (Wittkowsky et al 2004) on warfarin metabolism 
and INR, this study did not show a profound effect of these 
products on TWD.
Unfortunately, alcohol use was not stratiﬁ  ed into frequency, 
volume, or type consumed. Patients were simply asked if they 
used alcohol. Alcohol use has opposing effects on warfarin 
metabolism depending on whether it is consumed on a chronic, 
binge, or occasional basis (Ansell et al 2004). Individuals who 
chronically ingest alcohol experience increased warfarin clear-
ance through induction of CYP450 isoenzymes, which results in 
larger TWD requirements. Conversely, binge drinking inhibits 
the hepatic metabolism of warfarin, thus smaller amount TWD 
are needed. Likewise, tobacco use was not clearly established. 
Again, patients were simply asked if they used tobacco; the 
study was not designed to assess amount, frequency, or tobacco 
products used. Better assessment of these variables of alcohol 
and tobacco consumed may have produced a more predictive 
value on TWD. 
Of the 77 patients who completed the vitamin K survey, 
the average weekly intake did not prove to have a profound 
influence on TWD. As patients assessed their average 
weekly vitamin K intake just prior to their anticoagulation 
appointment, rather than concurrently, the retrospective 
completion of surveys could be subject to recall bias.
Interestingly, the adjusted R-squared value was also 
low, even for cross-sectional data. It indicates that the 
regression model as a whole only explains 8% of the 
variation in TWD. Both the low adjusted R-squared and 
the small number of statistically significant variables may 
be attributed to the relatively small sample size. Other 
recent literature have suggested similar findings (Singla 
and Morrill 2005). This may indicate that other variables, 
not analyzed in this study, may provide greater contribu-
tions to the determination of TWD. Sconce and colleagues 
(2005) suggest that genetics, specifically CYP 2C9 and 
VKORC1 genetic polymorphisms, may contribute up to 
55% of TWD variations.
Limitations
There are limitations inherent in this study. All information 
collected was via retrospective chart review. Furthermore, Therapeutics and Clinical Risk Management 2007:3(3) 504
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alcohol and tobacco use were not quantiﬁ  ed at each visit. 
Because height was not documented on every patient, 
BMI was unable to be calculated for each subject. Lastly, 
the relatively small sample size means that this study may 
not have been adequately powered to detect a statistically 
signiﬁ  cant difference between patient-speciﬁ  c factors, if a 
true difference did exist. 
Conclusion
In summary, from a retrospective chart review of 131 patients 
with therapeutic INRs, we found factors having the greatest 
inﬂ  uence on TWD to include the concomitant use of CYP-
inducing medications and age. Positive relationships between 
TWD and the following factors exist: use of CYP450 inducer, 
younger age, taller height, and African American ethnicity. 
Although it did appear that women required a smaller TWD 
than did men, we found that gender contributed only mildly. 
Further studies with a greater samples size in this area may 
more precisely predict the effect of patient-speciﬁ  c factors on 
the TWD. This information may help decrease consequences 
of supratherapetuic INRs while facilitating the achievement of 
therapeutic levels. In turn, this may result in decreased time of 
concomitant injectable anticoagulant use and/or hospitaliza-
tions which could ultimately decrease heathcare costs. 
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